Overview of the FDA Regulatory Process

Principles of Regenerative Medicine

Volumn , Issue , 2011, Pages 1145-1168

  Whittlesey, Kevin J ^a   Lee, Mark H ^b   Dang, Jiyoung M ^c   Colehour, Maegen ^c   Arcidiacono, Judith ^b   Lazarus, Ellen ^b   Kaplan, David S ^c   Fink, Donald ^b   Durfor, Charles N ^c   Batra, Ashok ^d,e   Hilbert, Stephen L ^f   Grayeski, Deborah Lavoie ^g   McFarland, Richard ^b   Witten, Celia ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e US Biotechnology and Pharma Consulting Group   (United States)

^f CHILDREN S MERCY HOSPITAL   (United States)

^g M Squared Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864256967     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381422-7.10063-X     Document Type: Chapter

References (72)

1. Anders J.J., Romanczyk T.B., Ilev I.K., Moges H., Longo L., Wu X., et al. Light supports neurite outgrowth of human neural progenitor cells in vitro: the role of P2Y receptors. IEEE J. Select. Topics Quantum Electron. 2008, 14(1):118-125.
2. Baird L.G., Christenson L., David J., Du Moulin G., Gentile F.T., Omstead D.R., et al. Voluntary guidance for the development of tissue-engineered products. Tissue Eng. 1998, 4:239-266.
3. Bauer S.R., Ruiz-Hidalgo M.J., Rudikoff E.K., Goldstein J., Laborda J. Modulated expression of the epidermal growth factor-like homeotic protein dlk influences stromal-cell-pre-B cell interactions, stromal cell adipogenesis, and pre-B-cell interleukin-7 requirements. Mol. Cell. Biol. 1998, 18:5247-5255.
4. Boyce S.T., Cooper M.L., Foreman T.J., Hansbrough J.F. Burn wound closure with cultured autologous keratinocytes and fibroblasts attached to a collagen-glycosaminoglycan substrate. JAMA 1989, 262:2125-2130.
5. Byrnes K.R., Waynant R.W., Ilev I.K., Wu X., Barna L., Smith K., et al. Light promotes regeneration and functional recovery and alters the immune response after spinal cord injury. Lasers Surg. Med. 2005, 36:171-185.
6. Carsin H., Ainaud P., Le Bever H., Rives J., Lakhel A., Stephanazzi J., et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized pateients: a five year single-center experience with 30 patients. Burns 2000, 26:379-387.
7. Cazalet C., Cherruau B., Jaffray P., Marien M., Schlotterer M., Toulon A., et al. Preliminary clinical studies of a biological skin equivalent in burned patients. Burns 1988, 14:326-330.
8. Currie L., Jones I., Martin R. A guide to biological skin substitutes. Br. J. Plast. Surg. 2002, 44:185-193.
9. Federal Food and Drugs Act, 1906, 34 Stat. 768, repealed by Food, Drug, and Cosmetic Act of 1938, 21 US C. Sec. 329(a).
10. Green H., Rheinwald J.G. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975, 6:331-343.
11. Haeseker B., Koch R., Teepe R.G. Randomized trial comparing cryopreserved cultured epidermal allografts with tulle-gras in the treatment of split-thickness skin graft donor sites. J. Trauma 1993, 35:850-854.
12. Hansbrough J.F., Dore C., Hansbrough W.B. Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. J. Burn Care Rehabil. 1992, 13:519-529.
13. Hoang B., Moos M., Vukicevic S., Luyten F.P. Primary structure and tissue distribution of Frzb, a novel protein related to Drosophila frizzled, suggest a role in human skeletal morphogenesis. J. Biol. Chem. 1996, 271:26131-26137.
14. Horvath-Arcidiacono J.Y.A., Evdokimov E., Lee M.H., Jones J., Rudenko L., Schneider B., et al. Regulation of xenogeneic porcine pancreatic islets. Xenotransplantation 2010, 17:329-337.
15. Lee M.H., Arcidiacono J.A., Bilek A.H., Wille J.J., Hamill C.A., Wonnacott K.M., et al. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the USA. Tissue Eng. 2010, 16B:41-54.
16. Lenas P., Moos M., Luyten F.P. Developmental engineering: a new paradigm for design and manufacture of cell based products. Part I: From three-dimensional cell growth to biomimetics of in vivo development. Tissue Eng. 2009, 15B:381-394.
17. Lenas P., Moos M., Luyten F.P. Developmental engineering: a new paradigm for the design and manufacture of cell based products. Part II: From genes to networks: tissue engineering from the viewpoint of systems biology and network science. Tissue Eng. 2009, 15B:395-422.
18. Lin K., Wang S., Julius M.A., Kitajewski J., Moos M., Luyten F.P. The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for the modulation of Wnt signaling. Proc. Natl. Acad. Sci. USA 1997, 94:11196-11200.
19. Marlowe D.E., Phillips P.J. FDA recognition of consensus standards in the premarket notification program. Biomedical Instrumentation and Technology 1998, 301-304. Hanley & Belfus, Philadelphia.
20. McCright B., Dang J.M., Hursh D.A., Kaplan D.S., Ballica R., Benton K., et al. Synopsis of the Food and Drug Administration - National Institute of Standards and Technology co-sponsored "In Vitro Analyses of Cell/Scaffold Products" Workshop. Tissue Eng. 2009, 15A:455-460.
21. Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group (2007). Advancing Tissue Science and Engineering: A Foundation for the Future. A Multi-Agency Strategic Plan. June 2007. Available at: . http://www.tissueengineering.gov/advancing_tissue_science_%26_engineerin g.pdf.
22. Ramadevi Raghunandan R., Ruiz-Hidalgo M., Ettinger R., Rudikoff E., Riggins P.S., Farnsworth R., et al. Dlk1 influences differentiation and function of B-lymphocytes. Stem Cells Dev. 2008, 17:495-507.
23. Ravenscroft-Chang M.S., Stohlman J.M., Molnar P., Natarajan A., Canavan H.E., Teliska M., et al. Altered calcium dynamics in cardiac cells grown on silane-modified surfaces. Biomaterials 2010, 31:602-607.
24. Simek S., Byrnes A., Bauer S. FDA perspectives on the use of the adenovirus reference material. Bioprocessing 2002, 1:40-42.
25. Smith J.S., Tian J., Lozier J.N., Byrnes A.P. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol. Ther. 2004, 9:932-941.
26. Smith J.S., Xu Z., Tian J., Stevenson S.C., Byrnes A.P. Interaction of systemically delivered adenovirus vector with Kupfer cells in mouse liver. Hum. Gene Ther. 2008, 19:547-554.
27. Thomas J.T., Prakash D., Moos M. CDMP-1/GDF5 has specific processing requirements that restrict its action to joint surfaces. J. Biol. Chem. 2006, 281:26725-26733.
28. Thomas J.T., Canelos P., Luyten F.P., Moos M. XSMOC-1 Inhibits BMP signaling downstream of receptor binding and is essential for xenopus neurulation. J. Biol. Chem. 2009, 284:18994-19005.
29. US Department of Health and Human Services, Food and Drug Administration (2006). Critical Path Opportunities List (March 2006). Available at: . http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathI nitiative/CriticalPathOpportunitiesReports/UCM077258.pdf.
30. US Food and Drug Administration (1997). Proposed Approach to the Regulation of Cellular and Tissue-Based Products (February 28, 1997). Available at: . http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe gulatoryInformation/Guidances/Tissue/UCM062601.pdf.
31. US Food and Drug Administration (2001a). Early Collaboration Meetings under the FDA Modernization Act (FDAMA), Final Guidance for Industry and for CDRH Staff (February 2001). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDo cuments/ucm073604.htm.
32. US Food and Drug Administration (2001b). Regulatory Information: Guidances: Guidance for Industry: Acceptance of Foreign Clinical Studies (March 2001). Available at: . http://www.fda.gov/RegulatoryInformation/Guidances/ucm124932.htm.
33. US Food and Drug Administration (2002). Guidance for Industry: Special Protocol Assessment (May 2002). Available at: . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM080571.pdf.
34. US Food and Drug Administration (2004a). Draft Guidance for Industry and FDA: Current Good Manufacturing Practice (cGMPs) for Combination Products (September 2004). Available at: . http://www.fda.gov/RegulatoryInformation/Guidances/ucm126198.htm.
35. US Food and Drug Administration (2004b). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice (September 2004). Available at: . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM070342.pdf.
36. US Food and Drug Administration (2006). Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment (June 2006). Available at: . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM071324.pdf.
37. US Food and Drug Administration (2010). Advisory Committee Calendar. Available at: . http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm.
38. US Food and Drug Administration, Center for Biologics Evaluation and Research (1993). Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (July 1993). Available at: . http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe gulatoryInformation/OtherRecommendationsforManufacturers/UCM062745.pdf.
39. US Food and Drug Administration, Center for Biologics Evaluation and Research (1997). Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (February 1997). Available at: . http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe gulatoryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf.
40. US Food and Drug Administration, Center for Biologics Evaluation and Research (1998a). Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy (March 1998). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/CellularandGeneTherapy/ucm072987.htm.
41. US Food and Drug Administration, Center for Biologics Evaluation and Research (1998b). Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biologic Products (May 1998). Available at: . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM078749.pdf.
42. US Food and Drug Administration, Center for Biologics Evaluation and Research (1998c). ICH Guidance on Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products (September 1998). Available at: . http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129103.p df.
43. US Food and Drug Administration, Center for Biologics Evaluation and Research (2000). Guidance for Industry, Formal Meetings with Sponsors and Applicants for PDUFA Products (February 2000). Available at: . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM079744.pdf.
44. US Food and Drug Administration, Center for Biologics Evaluation and Research (2001). Science and Research Special Topics: Running Clinical Trials, Information Sheets, and Notices on Good Clinical Practice in FDA-Regulated Clinical (April 2001). Available at: . http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/G uidancesInformationSheetsandNotices/default.htm.
45. US Food and Drug Administration, Center for Biologics Evaluation and Research (2003). Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans (April 2003). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/Xenotransplantation/ucm074354.htm.
46. US Food and Drug Administration, Center for Biologics Evaluation and Research (2005). Information on Submitting and Investigational New Drug Application for a Biological Product (June 2005). Available at: . http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/Inv estigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094309.htm.
47. US Food and Drug Administration, Center for Biologics Evaluation and Research (2006a). Cellular, Tissue and Gene Therapies Advisory Committee (Formerly Biological Response Modifiers Advisory Committee) (March 2006). Available at: . http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVa ccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/ default.htm.
48. US Food and Drug Administration, Center for Biologics Evaluation and Research (2006b). Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events (November 2006). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/CellularandGeneTherapy/ucm072957.htm.
49. US Food and Drug Administration, Center for Biologics Evaluation and Research (2006c). Guidances for Submission of INDs (January 2006). Available at: . http://www.fda.gov/cber/ind/indpubs.htm.
50. US Food and Drug Administration, Center for Biologics Evaluation and Research (2006d). Tissue & Tissue Products (April 2006). Available at: . http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/default.h tm.
51. US Food and Drug Administration, Center for Biologics Evaluation and Research (2006e). Xenotransplantation Action Plan, FDA Approach to the Regulation of Xenotransplantation (April 2006). Available at: . http://www.fda.gov/BiologicsBloodVaccines/Xenotransplantation/default.ht m.
52. US Food and Drug Administration, Center for Biologics Evaluation and Research (2007a). Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (August 2007). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/Tissue/ucm073964.htm.
53. US Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health (2007b). The Centers for Disease Control and Prevention: Processing of Orthopedic, Cardiovascular and Skin Allografts Workshop (October 2007). Available at: . http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/Workshops MeetingsConferences/TranscriptsMinutes/UCM054425.pdf.
54. US Food and Drug Administration, Center for Biologics Evaluation and Research (2008a). Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs) (April 2008). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/Xenotransplantation/ucm074131.htm.
55. US Food and Drug Administration, Center for Biologics Evaluation and Research (2008b). Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) (April 2008). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/CellularandGeneTherapy/ucm072587.htm.
56. US Food and Drug Administration, Center for Biologics Evaluation and Research (2009). Draft Guidance for Industry: Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) (January 2009). Available at: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/Tissue/ucm062693.htm.
57. US Food and Drug Administration, Center for Devices and Radiological Health (2000a). Apligraf® (Grafskin) (June 2000). Available at: . http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?nu m=p950032s016.
58. US Food and Drug Administration, Center for Devices and Radiological Health (2000b). Composite Cultured Skin (CCS) (February 2000). Available at: . http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?nu m=H990013.
59. US Food and Drug Administration, Center for Devices and Radiological Health (2001). OrCel Product Label (September 2001). Available at: . http://www.accessdata.fda.gov/cdrh_docs/pdf/P010016c.pdf.
60. US Food and Drug Administration, Center for Devices and Radiological Health (2002a). Device Advice: Premarket Approval (PMA) (November 2002). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarke tYourDevice/PremarketSubmissions/PremarketApprovalPMA/default.htm.
61. US Food and Drug Administration, Center for Devices and Radiological Health (2002b). PMA Postapproval Requirements: General Requirements (November 2002). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarke tYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm050422.htm.
62. US Food and Drug Administration, Center for Devices and Radiological Health (2003). Designating Humanitarian Use Devices (HUDs) (November 2003). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDo cuments/ucm071473.htm.
63. US Food and Drug Administration, Center for Devices and Radiological Health (2005a). Device Advice: Premarket Notification (510(k)) (February 2005). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarke tYourDevice/PremarketSubmissions/PremarketNotification510k/default.htm.
64. US Food and Drug Administration, Center for Devices and Radiological Health (2005b). CDRH Databases (December 2005). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ default.htm.
65. US Food and Drug Administration, Center for Devices and Radiological Health (2007). Epicel® (cultured epidermal autografts) (October 2007). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?nu m=H990002.
66. US Food and Drug Administration, Center for Devices and Radiological Health (2010a). Device Advice: Investigational Device Exemption (IDE). Available at: . http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarke tYourDevice/InvestigationalDeviceExemptionIDE/default.htm.
67. US Food and Drug Administration, Center for Devices and Radiological Health (2010b). Device Approvals and Clearances. Available at: . http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApp rovalsandClearances/default.htm.
68. US Food and Drug Administration, Center for Devices and Radiological Health (2010c). Device Approvals and Clearances: HDE Approvals. Available at: . http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApp rovalsandClearances/HDEApprovals/default.htm.
69. US National Institutes of Health, Office of Biotechnology Activities (2010). Recombinant DNA and Gene Transfer (September 2010). Available at: . http://oba.od.nih.gov/rdna_rac/rac_about.html.
70. US Public Health Service (2001). PHS Guideline on Infectious Disease Issues in Xenotransplantation (January 2001). Available at: . http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe gulatoryInformation/Guidances/Xenotransplantation/UCM092858.pdf.
71. Wang S., Krinks M., Moos M. Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts -3A, -5A, or -13.11. Biochem. Biophys. Res. Commun. 1997, 236:502-504.
72. Wang S., Krinks M., Lin K., Luyten F.P., Moos M. Frzb, a secretable protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 1997, 88:757-766.